Stockreport

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Therapeutics Ltd. - American Depositary Shares  (CMMB) 
PDF  —Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 [Read more]